News EQRx's low-price drugs mission ends with Revolution buy EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face